Answer
Neutropenia was very common in adults with relapsed or refractory multiple myeloma treated with talquetamab in MonumenTAL-1, occurring in 119 of 339 patients (35%), with Grade 3 or 4 neutropenia in 103 patients (30%).
Sources for this answer
- TALVEY 2 mg/mL solution for injectionJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.8 Undesirable effects · Version 11Document updated
Sources checked